Antioxidants and atherosclerosis

European Heart Journal, Supplement

Volumn 4, Issue B, 2002, Pages

  Violi, Francesco ^a   Micheletta, F ^a   Iuliano, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidants; Atherosclerosis; Oxidative stress

Indexed keywords

4,6 DI TERT BUTYL 2,3 DIHYDRO 5 HYDROXY 2,2 DIPENTYLBENZOFURAN; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; N,N' DIPHENYLPHENYLENEDIAMINE; OXYSTEROL; PROBUCOL; RAMIPRIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERY DIAMETER; ARTERY MEDIA; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; COMMON CAROTID ARTERY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG BIOAVAILABILITY; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; INTIMA; LIPID PEROXIDATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0141918657     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90011-8     Document Type: Review

References (53)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
2. Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
3. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
4. Esterbauer H, Gebicki J, Puhl H et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-90.
5. Pratico D, Iuliano L, Mauriello A et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 1028-34.
6. Palinski W, Ord VA, Plump AS et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb Vasc Biol 1994; 14: 605-16.
7. Calara F, Dimayuga P, Niemann A et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 18: 884-93.
8. Breuer O, Dzeletovic S, Lund E et al. The oxysterols cholest-5-ene-3β, 4α-diol, cholest-5ene-3β,4β-diol and cholestane-3β, 6α-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. Biochim Biophys Acta 1996; 1302: 145-52.
9. 2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147: 1-10.
10. Cracowski JL, Devillier P, Durand T et al. Vascular biology of the isoprostanes. J Vasc Res 2001; 38: 93-103.
11. Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999; 42: 1-28.
12. Steinberg D. Oxidative modification of LDL and atherosclerosis. Circulation 1997; 95: 1062-71.
13. Brown MS, Goldestein JL. Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 12: 223-61.
14. Kugiyama K, Kerns SA, Morrisett JD et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-2.
15. Frostegard J, Haegerstrand A, Gidlund M et al. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90: 119-26.
16. Frostegard J, Nilsson J, Haegerstrand A et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87: 904-8.
17. Schmidt K, Graier WF, Kostner GM et al. Activation of soluble guanylate cyclase by nitrovasodilators is inhibited by oxidized low-density lipoprotein. Biochem Biophys Res Commun 1990; 172: 614-9.
18. Weis JR, Pitas RE, Wilson BD et al. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J 1991; 5: 2459-65.
19. Iuliano L, Mauriello A, Sbarigia E et al. Radiolabeled native low-density lipoproteins injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque. Effect of Vitamin E supplementation. Circulation 2000; 101: 1249-54.
20. Ozer NK, Sirikci O, Taha S et al. Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits. Free Radic Biol Med 1998; 24: 226-33.
21. Sun J, Giraud DW, Moxley RA et al. Beta-carotene and alpha-tocopherol inhibit the development of atherosclerosis lesions in hypercholesterolemic rabbits. Int J Vitam Nutr Res 1997; 67: 155-63.
22. Williams RJ, Motteram JM, Sharp CH et al. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992; 94: 153-9.
23. Praticò D, Tangirala RK, Rader D et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in Apo E-deficient mice. Nat Med 1998; 4: 1189-92.
24. Lafont AM, Chai YC, Cornhill F et al. Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J Clin Invest 1995; 95: 1018-25.
25. Freyschuss A, Stiko-Rham A, Swedenborg J et al. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993; 91: 1282-8.
26. Sparrow CP, Doebber TW, Olszewski J et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine. J Clin Invest 1992; 89: 1885-91.
27. Tangirala RK, Casanada F, Miller E et al. Effect of the antioxidant N,N′-diphenyl-phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1995; 15: 1625-30.
28. Cynshi O, Kawabe Y, Suzuki T et al. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc Natl Acad Sci USA 1998; 95: 10123-8.
29. Kuzuya M, Kuzuya F. Probucol as antioxidant and antiatherogenic drug. Free Rad Biol Med 1992; 89: 1885-91.
30. Steinberg D, Parthasarathy S, Carew TE. In vivo inhibition of foam cells development by probucol in Watanabe rabbits. Am J Cardiol 1988; 62: 6B-12B.
31. Shaish A, Daugherty A, O'Sullivan F et al. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995; 96: 2075-82.
32. Bird DA, Tangirala RK, Fruebis J et al. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J Lipid Res 1998; 39: 1079-90.
33. Zhang SH, Reddick RL, Avdievich E et al. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoproteins E-deficient mice. J Clin Invest 1997; 99: 2858-66.
34. Moghadasian MH, McManus BM, Godin DV et al. Proatherogenic and antiatherogenic effects of probucol in apolipoproteins E-deficient mice: possible mechanism of action. Circulation 1999; 99: 1733-9.
35. Iuliano L, Piccheri C, Coppola I et al. Fluorescence quenching of dipyridamole associated to peroxyl radical scavenging: a versatile probe to measure the chain breaking antioxidant activity of biomolecules. Biochim Biophys Acta 2000; 1474: 177-82.
36. Rapola JM, Virtamo J, Ripatti S et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20.
37. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781-6.
38. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.
39. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154-60.
40. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
41. Anonymous. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
42. Salonen JT, Nyyssönen K, Salonen R et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomised trial of the effect of vitamins E and C on 3-years progression of carotid atherosclerosis. J Intern Med 2000; 248: 377-86.
43. Lonn EM, Yusuf S, Dzavik V et al. Effect of ramipril and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001: 103: 919-25.
44. Tardif JC, Cote G, Lesperance J et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-72.
45. Acuff RV, Thedford SS, Hidiroglou NN et al. Relative bioavailability of RRR- and all-rac-alpha-tocopheryl acetate in humans: studies using deuterated compounds. Am J Clin Nutr 1994; 60: 397-402.
46. Traber MG, Flsner A, Brigelius-Flohé R. Synthetic as compared with natural vitamin E is preferentially excreted as α-CEHC in human urine: studies using deuterated α-tocopheryl acetates. FEBS Lett 1998; 437: 145-8.
47. Burton GW, Traber MG, Acuff RV et al. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr 1998; 67: 669-84.
48. Violi F, Micheletta F, Iuliano L. Antioxidant strategy for cardiovascular disease. Lancet 2001; 357: 1704-6.
49. Hosomi A, Arita M, Sato Y et al. Affinity for α-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett 1997; 409: 105-8.
50. Violi F, Micheletta F, Iuliano L. Vitamin E, atherosclerosis, and thrombosis. Thromb Haemost 2001; 85: 766-70.
51. Meagher EA, Barry OP, Lawson JA et al. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001; 285: 1178-82.
52. Zieden B, Kaminskas A, Kristenson M et al. Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 967-71.
53. Salonen JT, Nyyssonen K, Salonen R et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 1997; 95: 840-5.